Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIL 93

Next Previous
Drug Profile

MIL 93

Alternative Names: MIL-93; Recombinant humanized monoclonal antibody MIL93 -Beijing Mabworks Biotech

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Mabworks Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 09 Jan 2026 Phase I/II development for Solid tumours is ongoing in China (Mabworks Biotech pipeline, January 2025)
  • 09 Jan 2026 Mabwork Biotech has patent protection for ADCC-enhanced antibody platform in China, Hong Kong, Japan, South Korea, Australia, New Zealand, Canada, Europe, and the United States (Mabworks Biotech pipeline, January 2026)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top